Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

TAVR still a safe treatment option for immunocompromised patients
While patients with a weakened immune system are still more likely to die after TAVR than other patients, those deaths are largely not related to the procedure or any other cardiovascular issues. This new meta-analysis explored data from a variety of clinical trials.
Pope welcomes cardiologists to Vatican City
Pope Leo XIV told interventional cardiologists their work “stands at the crossroads of science, compassion and ethical responsibility.” When they treat patients, he added, they are treating the heart “both physically and metaphorically, bringing relief to those who suffer.”
Edwards Lifesciences shares positive outlook for 2026, pointing to continued importance of TAVR
The company expects TAVR sales alone to be as high as $4.9 billion in 2026. Other minimally invasive therapies are projected to make a major impact as well.
FDA commissioner claims Biden administration hid heart risks of COVID-19 vaccines from public
The allegation came days after an internal FDA memo linked the vaccines to the deaths of multiple children. A group of former FDA commissioners pushed back against the content of that memo.
Community Health Systems sells ambulatory diagnostics segment to Labcorp for $194M
The all-cash deal is expected to be finalized in April 2026. With this divestment of its ambulatory labs, Tennessee-based Community Health Systems said it will be better able to focus on its core patient care business.

TAVR still a safe treatment option for immunocompromised patients

While patients with a weakened immune system are still more likely to die after TAVR than other patients, those deaths are largely not related to the procedure or any other cardiovascular issues. This new meta-analysis explored data from a variety of clinical trials.

Pope welcomes cardiologists to Vatican City

Pope Leo XIV told interventional cardiologists their work “stands at the crossroads of science, compassion and ethical responsibility.” When they treat patients, he added, they are treating the heart “both physically and metaphorically, bringing relief to those who suffer.”

Edwards Lifesciences shares positive outlook for 2026, pointing to continued importance of TAVR

The company expects TAVR sales alone to be as high as $4.9 billion in 2026. Other minimally invasive therapies are projected to make a major impact as well.

artificial intelligence ai in healthcare

FDA commissioner claims Biden administration hid heart risks of COVID-19 vaccines from public

The allegation came days after an internal FDA memo linked the vaccines to the deaths of multiple children. A group of former FDA commissioners pushed back against the content of that memo.

Community Health Systems sells ambulatory diagnostics segment to Labcorp for $194M

The all-cash deal is expected to be finalized in April 2026. With this divestment of its ambulatory labs, Tennessee-based Community Health Systems said it will be better able to focus on its core patient care business.

Hotwire Transseptal Access System Atraverse Medical

FDA clears new left-heart access system from Atraverse Medical

The Hotwire Transseptal Access System includes the Hotwire RF Generator and Hotwire RF Guidewire, giving electrophysiologists the tools they need for left-heart access.

MiniMed 780G system integrated with Instinct sensors manufactured by Abbott.

Medtronic launches new diabetes tech integrated with Abbott sensor

Two of the world's leading healthcare companies have partnered on a new treatment option for patients with type 1 diabetes.

$V-Wave has gained considerable attention or its Ventura Interatrial Shunt System, a small implantable device designed to reduce pressure on the left atrium and the lungs in patients with heart failure with reduced ejection fraction (HFrEF). The Ventura device includes a nitinol hourglass-shaped frame that anchors to the patient’s fossa ovalis in a way that prevents migration or embolization. It is implanted via an interventional procedure with fluoroscopy and echocardiography guidance.$

FDA panel votes against approving first-of-its-kind heart failure device

All 15 members of the FDA's Circulatory System Devices Panel agreed that more data is required to confirm the new device from Johnson & Johnson MedTech is effective. Will the agency agree with these recommendations? Only time will tell.